美沙拉嗪联合匹维溴铵治疗肠易激综合征的疗效观察

目的探讨美沙拉嗪肠溶片联合匹维溴铵片治疗肠易激综合征的临床疗效。方法选取2014年10月—2017年10月在西安市中心医院治疗的134例肠易激综合征患者作为研究对象,根据治疗方案的差别将患者随机分为对照组(67例)和治疗组(67例)。对照组患者口服匹维溴铵片,50mg/次,4次/d;治疗组患者在对照组治疗的基础上口服美沙拉嗪肠溶片,1g/次,4次/d。两组患者均连续治疗4周。观察两组患者的临床疗效,比较两组患者的临床症状消失时间。结果治疗后,对照组和治疗组总有效率分别为80.59%、94.03%,两组比较差异具有统计学意义(P0.05)。治疗后,治疗组患者腹痛、腹泻、腹胀消失时间显著短于对照组患者,两组比较差异具有统计学意义(P0.05)。结论美沙拉嗪肠溶片联合匹维溴铵片治疗肠易激综合征具有较好的临床疗效,能显著改善患者临床症状,具有一定的临床推广应用价值。

Clinical observation of mesalazine combined with pinaverium bromide in treatment of irritable bowel syndrome

Objective To investigate the clinical efficacy of Mesalazine Enteric-coated Tablets combined with Pinaverium Bromide Tablets in treatment of irritable bowel syndrome. Methods Patients (134 cases) with irritable bowel syndrome in Xi''an Central Hospital from October 2014 to October 2017 were divided into control (67 cases) and treatment (67 cases) groups according to the difference of treatment regimen. Patients in the control group were po administered with Pinaverium Bromide Tablets, 50 mg/time, four times daily. Patients in the treatment group were po administered with Mesalazine Enteric Coated Tablets on the basis of the control group, 1 g/time, four times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the disappearance times of clinical symptoms in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 80.59% and 94.03%, respectively, and there were differences between two groups (P<0.05). After treatment, the disappearance times of abdominal pain, diarrhea, and abdominal distension in the treatment group were shorter than those in the control group, and there were differences between two groups (P<0.05). Conclusion Mesalazine Enteric-coated Tablets combined with Pinaverium Bromide Tablets has clinical curative effect in treatment of irritable bowel syndrome, can significantly improve the clinical symptoms of patients, which has a certain clinical application value.